Paper40891997
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
Vlaming M and 16 others. BJU Int, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer. Papers, record 40891997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40891997
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| Germ-Line Mutation | Major topic |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Aged | |
| Prevalence | |
| Ataxia Telangiectasia Mutated Proteins | |
| Checkpoint Kinase 2 | |
| Fanconi Anemia Complementation Group N Protein | |
| Netherlands | |
| Genetic Testing | |
| BRCA1 Protein | |
| Female | |
| Genetic Predisposition to Disease | |
| BRCA2 Protein |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| KWF Kankerbestrijding | PubMed |
Source PubMed
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29439820 | Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. | Eur Urol | 2018 | https://conductscience.org/library/papers/29439820 | PubMed |
| 2 | 39209703 | Protein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequence data. | J Med Genet | 2024 | https://conductscience.org/library/papers/39209703 | PubMed |
| 3 | 27649974 | Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. | Am J Surg | 2016 | https://conductscience.org/library/papers/27649974 | PubMed |
| 4 | 29915322 | Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. | Br J Cancer | 2018 | https://conductscience.org/library/papers/29915322 | PubMed |
| 5 | 31537406 | Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. | Eur Urol | 2019 | https://conductscience.org/library/papers/31537406 | PubMed |
| 6 | 38484203 | Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38484203 | PubMed |
| 7 | 11967536 | Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. | Nat Genet | 2002 | https://conductscience.org/library/papers/11967536 | PubMed |
| 8 | 33792945 | Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. | Prostate | 2021 | https://conductscience.org/library/papers/33792945 | PubMed |
| 9 | 29801018 | Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. | JAMA | 2018 | https://conductscience.org/library/papers/29801018 | PubMed |
| 10 | 29368341 | Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. | Prostate | 2018 | https://conductscience.org/library/papers/29368341 | PubMed |
| 11 | 36581909 | Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. | BMC Cancer | 2022 | https://conductscience.org/library/papers/36581909 | PubMed |
| 12 | 27433846 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27433846 | PubMed |
| 13 | 8345587 | Hereditary prostate cancer: epidemiologic and clinical features. | J Urol | 1993 | https://conductscience.org/library/papers/8345587 | PubMed |
| 14 | 37018966 | Patients' experiences with pre-test genetic counseling provided by breast cancer healthcare professionals: Results from a large prospective multicenter study. | Breast | 2023 | https://conductscience.org/library/papers/37018966 | PubMed |
| 15 | 26000489 | Integrative clinical genomics of advanced prostate cancer. | Cell | 2015 | https://conductscience.org/library/papers/26000489 | PubMed |
| 16 | 26629066 | CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. | Int J Clin Exp Med | 2015 | https://conductscience.org/library/papers/26629066 | PubMed |
| 17 | 30730552 | Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/30730552 | PubMed |
| 18 | 33471991 | Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33471991 | PubMed |
| 19 | 32741080 | Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer. | Breast J | 2020 | https://conductscience.org/library/papers/32741080 | PubMed |
| 20 | 38811422 | Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow. | Fam Cancer | 2024 | https://conductscience.org/library/papers/38811422 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42667419 | Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer. | Hum Genet | 2026 | https://conductscience.org/library/papers/42667419 | PubMed |
| 41595443 | Prevalence and Clinical Associations of Germline DDR Variants in Prostate Cancer: Real-World Evidence from a 122-Patient Turkish Cohort. | Genes (Basel) | 2025 | https://conductscience.org/library/papers/41595443 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATM | 472 | PubTator's text mining | https://conductscience.org/library/genes/472 | NCBI Gene |
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| CHEK2 | 11200 | PubTator's text mining | https://conductscience.org/library/genes/11200 | NCBI Gene |
| PALB2 | 79728 | PubTator's text mining | https://conductscience.org/library/genes/79728 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40891997
GET https://conductscience.org/api/papers/v1/40891997/references?page=2